I'd love to see a study with a combination of intravenous and local injections of MSCs for SR-GVHD. I've got a feeling that the results would be amazing. Given the success of direct application of MSC for perianal fistula it stands to reason that shifting the focus further up the GI tract (to where the issues are truly life threatening due leaky gut and abscesses in the colon inviting infection and organ failure) that there would be additional improvements in mortality over and above those shown in the intravenous treatment.
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-35
-
- There are more pages in this discussion • 321 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 122380 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |